Spark Therapeutics Inc

Spark Therapeutics — HSG 2024 Annual Meeting

21 slides from Spark Therapeutics's conference presentation, November 2024

  1. Slide 1: Advancing investigational SPK-10001 into a First-in-Human study

    Advancing investigational SPK-10001 into a First-in-Human study HSG 2024 Annual Meeting Cincinnati, OH November 7-9, 2024 1

  2. Slide 2: Disclaimer

    Disclaimer SPK-10001 is investigational and has not been approved by any health authority. This presentation contains nonclinical data regarding an investigational use of SPK-10001. These data are intended to be hypothesis-generating. The clinical significance of these nonclinical data has not been

  3. Slide 3: Speaker disclosure

    Speaker disclosure Juha Savola is a salaried employee of Spark Therapeutics, Inc., and a holder of shares and options in Roche Holding AG 3

  4. Slide 4: Huntington's disease (HD) is a fatal neurodegenerative syndrome

    Huntington’s disease (HD) is a fatal neurodegenerative syndrome Causal toxic mHTT protein Pathological/clinical Cellular dysfunction1 from defective HTT gene1 representation2-4 Atrophy • Brain tissue loss Impaired axonal transport • Muscle wasting Mitochondrial dysfunction • Weight loss Synaptic dys

  5. Slide 5: Investigational SPK-10001 is designed to slow down or halt HD progression

    Investigational SPK-10001 is designed to slow down or halt HD progression microRNA to reduce synthesis of mHTT in the key brain structure relevant to HD • SPK-10001 is expected to deliver a non-allele specific microRNA targeting huntingtin mRNA • Reduction in disease-relevant toxic mutant huntingtin

  6. Slide 6: Preclinical evidence shows HTT reduction in the caudate and putamen in an animal model

    Preclinical evidence shows HTT reduction in the caudate and putamen in an animal model TARGET BRAIN REGIONS (NHP) CAUDATE (CAU) PUTAMEN (PUT) Note: HTT refers to only wild-type HTT NHP, non-human primate; KD, knockdown Data on File. Spark Therapeutics, Inc. Philadelphia, PA Brain graphic created wit

  7. Slide 7: Reduction of HTT protein comparable between 3 and 12 months after administration

    Reduction of HTT protein in the caudate and putamen comparable between 3 and 12 months after administration in an animal model TARGET BRAIN REGIONS (NHP) Note: HTT refers to only wild-type HTT NHP, non-human primate; KD, knockdown Data on File. Spark Therapeutics, Inc. Philadelphia, PA Brain graphic

  8. Slide 8: Preclinical development of the neurosurgical approach

    Preclinical development of the neurosurgical approach Optimizing surgical trajectories, volume, and injection speed reduced trauma and improved coverage of target brain region in NHPs Initial surgical procedure NHP surgical procedure* o 2 trajectories per hemisphere (1 in putamen and 1 in caudate) o

  9. Slide 9: Robust and predictable biodistribution of SPK-10001 in the key target structures in NHPs

    Robust and predictable biodistribution of SPK-10001 in the key target structures in NHPs CAUDATE (CAU) PUTAMEN (PUT) EXTERNAL GLOBUS PALLIDUS NHP, non-human primates Data on File. Spark Therapeutics, Inc. Philadelphia, PA Brain graphic created with SBA Composer of the Scalable Brain Atlas (Clabrese

  10. Slide 10: Dose responsive HTT mRNA and HTT protein reductions across several brain regions

    Dose responsive HTT mRNA and HTT protein reductions across several brain regions after SPK-10001 in NHPs • In the context of hypothetized process for the HD pathology, potentially meaningful HTT protein reductions shown in basal ganglia, thalamus, and cortex in NHPs Data on File. Spark Therapeutics,

  11. Slide 11: Longitudinal MRI showed no signal of increased lateral ventricle volumes

    Longitudinal MRI analysis showed no signal of increased lateral ventricle volumes after SPK-10001 in NHPs Lateral Ventricle Volume 400 300 (mm3) 200 L R L R L R L R 100 Control HIGH DOSE MID DOSE LOW DOSE 0 30 60 30 60 30 60 30 60 30 60 30 60 30 60 30 60 5 5 5 5 5 5 5 5 0 0 0 0 0 0 0 0 36 36 36 36 3

  12. Slide 12: Caudate and putamen volumes vary greatly between individuals

    Caudate and putamen volumes vary greatly between individuals as part of the disease progression, even within the same “clinical progression” stage of HD Gen-HD1 (red dots, N=120) and Gen-HD1 shows inter-individual spread Predict/Track/Image-HD (box plots, N=575) show At the time of clinical diagnosi

  13. Slide 13: Use the NHP target volume to inform further clinical investigation and dosing

    Use the NHP target volume to inform further clinical investigation and dosing Convert pharmacodynamic NHP data from vg/brain to vg/mm3 NHP HTT mRNA 1.4 • Preclinical NHP data NHP Putamen (normalized to HPRT1) 1.2 inform dose estimation to 1.0 HTT mRNA be tested in clinical 0.8 program 0.6 50% 0.4 •

  14. Slide 14: Use the NHP target volume to inform further clinical investigation and dosing

    Use the NHP target volume to inform further clinical investigation and dosing Convert pharmacodynamic NHP data from vg/brain to vg/mm3 NHP HTT mRNA 1.4 • Preclinical NHP data NHP Putamen (normalized to HPRT1) 1.2 inform dose estimation to 1.0 HTT mRNA be tested in clinical 0.8 program 0.6 50% 0.4 •

  15. Slide 15: Planned SPK-10001-101 First-in-Human Study

    Planned SPK-10001-101 First-in-Human Study 15

  16. Slide 16: Phase 1/2 First-in-Human study planned: key inclusion criteria

    Phase 1/2 First-in-Human study planned in HD-ISS late Stage 2 and early Stage 3 subjects Key Inclusion Criteria: Concomitant medications if stable pre-study and • CAG repeat length ≥40 anticipated to remain stable for 12 months post- • Striatal atrophy level following HD-ISS Stage 1 dosing criteria

  17. Slide 17: Phase 1/2 First-in-Human study planned: key exclusion criteria

    Phase 1/2 First-in-Human study planned in HD-ISS late Stage 2 and early Stage 3 subjects Key Exclusion Criteria: • A safe trajectory is not able to be identified for targeting placement of the SmartFlow cannula into the caudate or putamen on both sides of the brain due to extent of atrophy or other

  18. Slide 18: Study design

    Study design • Huntington Study Group as the CRO • Neurosurgical administration of SPK-10001 developed with ClearPoint technology • Joint Monitoring Committee to oversee and monitor conduct of the study to ensure safety of participants • Study to be conducted in the US Data on File. Spark Therapeuti

  19. Slide 19: Neurosurgical administration of SPK-10001 in the caudate and putamen

    Neurosurgical administration of SPK-10001 in the caudate and putamen • Intraparenchymal infusions to the caudate and putamen using convection-enhanced delivery under intraoperative MRI guidance to visualize and optimize coverage of the target regions ▪ Bilateral simultaneous infusions along the long

  20. Slide 20: Study outcomes

    Study outcomes Primary objectives: Safety and tolerability, and preliminary efficacy 24 months after SPK-10001 administration • Preliminary efficacy based on Total Functional Capacity • Secondary endpoints for the preliminary efficacy: ▪ Huntington’s Disease Digital Motor Score ▪ Composite Unified H

  21. Slide 21: Acknowledgements

    Acknowledgements Most importantly, we want to extend our gratitude to the HD community, and the community members who spent time with us and supported our work on this study design We also want to acknowledge the valuable support and insightful guidance to improve the study design which we have rece

Spark Therapeutics — HSG 2024 Annual Meeting on 6ix